Condition: Breast Cancer Early Stage Breast Cancer (Stage 1-3) · Sponsor: European Institute of Oncology
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
This description comes directly from the study's public registry record.
Paola Zagami · 00390294372437 · paola.zagami@ieo.it
Always discuss trial participation with your own doctor first.
| Istituto Europeo di Oncologia | Milan, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06723990